Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK.

Sci Transl Med. 2018 Mar 14;10(432). pii: eaag0945. doi: 10.1126/scitranslmed.aag0945.

2.

Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS.

Br J Radiol. 2017 Aug;90(1076):20170134. doi: 10.1259/bjr.20170134. Epub 2017 Jun 14.

3.

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade.

Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL.

Cancer Med. 2017 Jul;6(7):1827-1836. doi: 10.1002/cam4.1103. Epub 2017 May 31.

4.

The modified swirl sedimentation tanks for water purification.

Ochowiak M, Matuszak M, Włodarczak S, Ancukiewicz M, Krupińska A.

J Environ Manage. 2017 Mar 15;189:22-28. doi: 10.1016/j.jenvman.2016.12.023. Epub 2016 Dec 18.

PMID:
28002778
5.

PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.

Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel JA, Krop IE, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, Duda DG, Jain RK, Fukumura D.

Clin Cancer Res. 2016 Jun 15;22(12):2993-3004. doi: 10.1158/1078-0432.CCR-15-1839. Epub 2016 Feb 9.

6.

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.

7.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

8.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.

9.

Cardiac and inflammatory biomarkers do not correlate with volume of heart or lung receiving radiation.

Kuo AH, Ancukiewicz M, Kozak KR, Yock TI, Padera TP.

Radiat Oncol. 2015 Jan 9;10:5. doi: 10.1186/s13014-014-0324-1.

10.

Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer.

Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, Cusack JC, Drapek LC, Kovalchuk N, Markowski M, Napolitano B, Nyamwanda J, Ryan DP, Wolfgang J, Kachnic LA, Wo JY.

Pract Radiat Oncol. 2015 May-Jun;5(3):e113-8. doi: 10.1016/j.prro.2014.09.003. Epub 2014 Oct 30.

PMID:
25424587
11.

Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.

Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK.

J Natl Cancer Inst. 2014 Jul 31;106(8). pii: dju187. doi: 10.1093/jnci/dju187. Print 2014 Aug. No abstract available.

PMID:
25082335
12.

Long-term cosmetic outcomes and toxicities of proton beam therapy compared with photon-based 3-dimensional conformal accelerated partial-breast irradiation: a phase 1 trial.

Galland-Girodet S, Pashtan I, MacDonald SM, Ancukiewicz M, Hirsch AE, Kachnic LA, Specht M, Gadd M, Smith BL, Powell SN, Recht A, Taghian AG.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):493-500. doi: 10.1016/j.ijrobp.2014.04.008. Epub 2014 May 29.

PMID:
24880212
13.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.

14.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

15.

Long-term survival after distant metastasis in patients with oropharyngeal cancer.

McBride SM, Busse PM, Clark JR, Wirth LJ, Ancukiewicz M, Chan AW.

Oral Oncol. 2014 Mar;50(3):208-12. doi: 10.1016/j.oraloncology.2013.10.020. Epub 2013 Dec 31.

PMID:
24387975
16.

Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.

Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS, Lillemoe KD, Fernandez-del Castillo C, Hong TS.

Radiother Oncol. 2014 Jan;110(1):160-4. doi: 10.1016/j.radonc.2013.10.027. Epub 2013 Nov 11.

PMID:
24231241
17.

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64. doi: 10.1073/pnas.1318022110. Epub 2013 Nov 4.

18.

Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes.

Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS.

Cancer. 2014 Jan 15;120(2):238-43. doi: 10.1002/cncr.28398. Epub 2013 Oct 2.

19.

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.

Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K.

Clin Cancer Res. 2013 Dec 1;19(23):6614-23. doi: 10.1158/1078-0432.CCR-13-1442. Epub 2013 Oct 2.

20.

Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.

Aizer AA, Ancukiewicz M, Nguyen PL, Macdonald SM, Yock TI, Tarbell NJ, Shih HA, Loeffler JS, Oh KS.

J Neurooncol. 2013 Dec;115(3):411-9. doi: 10.1007/s11060-013-1237-9. Epub 2013 Sep 21.

PMID:
24057324
21.

Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.

Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX.

J Hematol Oncol. 2013 Jul 10;6:51. doi: 10.1186/1756-8722-6-51.

22.

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK.

Neuro Oncol. 2013 Aug;15(8):1079-87. doi: 10.1093/neuonc/not082. Epub 2013 Jul 4.

23.

Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.

Choi NC, Chun TT, Niemierko A, Ancukiewicz M, Fidias PM, Kradin RL, Mathisen DJ, Lynch TJ, Fischman AJ.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):832-41. doi: 10.1007/s00259-013-2348-4. Epub 2013 Feb 12.

24.

Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG.

Clin Cancer Res. 2013 Mar 15;19(6):1557-66. doi: 10.1158/1078-0432.CCR-12-3041. Epub 2013 Jan 29.

25.

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi: 10.1073/pnas.1215397109. Epub 2012 Oct 8.

26.

Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.

Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L.

Int J Biol Markers. 2013 Apr 23;28(1):17-23. doi: 10.5301/JBM.2012.9580.

PMID:
23015398
27.

TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.

Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16618-23. doi: 10.1073/pnas.1117610109. Epub 2012 Sep 20.

28.

Dye-enhanced multimodal confocal imaging as a novel approach to intraoperative diagnosis of brain tumors.

Snuderl M, Wirth D, Sheth SA, Bourne SK, Kwon CS, Ancukiewicz M, Curry WT, Frosch MP, Yaroslavsky AN.

Brain Pathol. 2013 Jan;23(1):73-81. doi: 10.1111/j.1750-3639.2012.00626.x. Epub 2012 Aug 28.

PMID:
22882328
29.

Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology.

Ancukiewicz M, Miller CL, Skolny MN, O'Toole J, Warren LE, Jammallo LS, Specht MC, Taghian AG.

Breast Cancer Res Treat. 2012 Aug;135(1):145-52. doi: 10.1007/s10549-012-2111-8. Epub 2012 Jun 19. Erratum in: Breast Cancer Res Treat. 2012 Nov;136(2):623.

30.

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG.

PLoS One. 2012;7(6):e38231. doi: 10.1371/journal.pone.0038231. Epub 2012 Jun 12.

31.

External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study.

Pashtan IM, Recht A, Ancukiewicz M, Brachtel E, Abi-Raad RF, D'Alessandro HA, Levy A, Wo JY, Hirsch AE, Kachnic LA, Goldberg S, Specht M, Gadd M, Smith BL, Powell SN, Taghian AG.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e271-7. doi: 10.1016/j.ijrobp.2012.04.019. Epub 2012 May 30.

32.

Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.

Chen RC, Mamon HJ, Ancukiewicz M, Killoran JH, Crowley EM, Blaszkowsky LS, Wo JY, Ryan DP, Hong TS.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e513-7. doi: 10.1016/j.ijrobp.2012.01.013. Epub 2012 Mar 19.

PMID:
22436781
33.

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).

Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK.

PLoS One. 2012;7(2):e26331. doi: 10.1371/journal.pone.0026331. Epub 2012 Feb 7.

34.

Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG.

Oncologist. 2012;17(2):212-9. doi: 10.1634/theoncologist.2011-0321. Epub 2012 Feb 2.

35.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ.

Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.

36.

A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy.

Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemierko A, Willers H, Choi NC, Christiani DC.

Cancer. 2012 Jul 15;118(14):3654-65. doi: 10.1002/cncr.26667. Epub 2011 Dec 5.

37.

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK.

Cancer Res. 2012 Jan 15;72(2):402-7. doi: 10.1158/0008-5472.CAN-11-2464. Epub 2011 Nov 29. Erratum in: Cancer Res. 2012 Jan 15;72(2):doi:10.1158/0008-5472.CAN-12-0113. Cancer Res. 2012 Mar 1;72(5):1316.

38.

Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial.

Hattangadi JA, Powell SN, MacDonald SM, Mauceri T, Ancukiewicz M, Freer P, Lawenda B, Alm El-Din MA, Gadd MA, Smith BL, Taghian AG.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):791-800. doi: 10.1016/j.ijrobp.2011.09.003. Epub 2011 Nov 16.

39.

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.

Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK.

Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun;4(1):26-33.

40.

Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes.

Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, Wright P, Peterson MW, Rock P, Hyzy RC, Anzueto A, Truwit JD; National Institutes of Health National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network.

Crit Care Med. 2011 Dec;39(12):2665-71. doi: 10.1097/CCM.0b013e318228234b.

41.

Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older.

Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e735-41. doi: 10.1016/j.ijrobp.2010.12.056. Epub 2011 Mar 4.

PMID:
21377289
42.

Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva.

Mak RH, Halasz LM, Tanaka CK, Ancukiewicz M, Schultz DJ, Russell AH, Viswanathan AN.

Gynecol Oncol. 2011 Jan;120(1):101-7. doi: 10.1016/j.ygyno.2010.09.004. Epub 2010 Oct 14.

PMID:
20950845
43.

Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.

Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1081-90. doi: 10.1016/j.ijrobp.2010.07.024. Epub 2010 Oct 6.

44.

Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK.

Clin Cancer Res. 2011 Feb 15;17(4):918-27. doi: 10.1158/1078-0432.CCR-10-0515. Epub 2010 Sep 15.

45.

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.

Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK.

Oncologist. 2010;15(8):845-51. doi: 10.1634/theoncologist.2010-0030. Epub 2010 Jul 28.

46.

Standardized method for quantification of developing lymphedema in patients treated for breast cancer.

Ancukiewicz M, Russell TA, Otoole J, Specht M, Singer M, Kelada A, Murphy CD, Pogachar J, Gioioso V, Patel M, Skolny M, Smith BL, Taghian AG.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1436-43. doi: 10.1016/j.ijrobp.2010.01.001. Epub 2010 Jun 3.

47.

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK.

Oncologist. 2010;15(6):577-83. doi: 10.1634/theoncologist.2010-0029. Epub 2010 May 18.

48.

Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation.

Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES, Munzenrider JE.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):842-6. doi: 10.1016/j.ijrobp.2009.12.018. Epub 2010 May 14.

PMID:
20472356
49.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK.

J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10.

50.

Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?

Duda DG, Ancukiewicz M, Jain RK.

J Clin Oncol. 2010 Jan 10;28(2):183-5. doi: 10.1200/JCO.2009.24.8021. Epub 2009 Nov 30. No abstract available.

PMID:
19949009

Supplemental Content

Loading ...
Support Center